GET THE APP

Aggressive phenotype of triple-negative breast cancer stem cells | 3770
Transcriptomics: Open Access

Transcriptomics: Open Access
Open Access

ISSN: 2329-8936

+44 1223 790975

Aggressive phenotype of triple-negative breast cancer stem cells (TNBC-CSC)


International Conference on Transcriptomics

July 27-29, 2015 Orlando, USA

Punit Kaur1,Tarundeep Singh2, Moses Galukande3, Sunil Krishnan4 and Alexzander Asea1

Scientific Tracks Abstracts: Transcriptomics

Abstract :

Recent studies on surface receptors and gene expression of breast tumors have come up with a term Triple-Negative Breast Cancer (TNBC), creating a phenotype and disease quite distinct from that seen in Triple-Positive Breast Cancer (TPBC), which is a much more aggressive disease without tumor-specific treatment options. Although slightly responsive to chemotherapy, TNBC is more difficult to treat and generally insensitive to most available hormonal or targeted therapeutic agents. We constructed a population of TNBC and TPBC by stable transfection of 4T1 cells with the rat HER2 gene, ER gene and PgR gene to avoid non-specific immune responses, and sorting using flow cytometry. Cells were injected into mice and HT was achieved using gold nanoshells, and live animal imaging was used to non-invasively measure tumor growth. We uncovered two phenotypically distinct populations of cancer stem cells (CSC) based on the expression of CD24+/ALDH-1+/CD44 high cells, and demonstrated that they proliferate significantly faster than CD24-/ALDH-1-/CD44 low cells or wild type controls. Exposure of TNBC-CSC and TPBC-CSC to HT, RT or HT+RT result in differential release of Hsp72. Under all conditions tested, TPBC-CSC released significantly more Hsp72 than TNBC-CSC. Western blot analysis of the 1.17 g/ml density exosome fraction (obtained from sucrose gradient ultracentrifugation) revealed that TPBC-CSC contained significantly more Hsp72 within the exosomes than TNBC-CSC. Taken together this investigation determined that the use of combined HT+RT in combination with current anti-breast cancer chemotherapeutic, known as the triple modality will be beneficial to patients with TNBC.

Biography :

Punit Kaur finished her BSc in 1999 with Botany, Zoology and Chemistry from Punjab University, Chandigarh, India. Then she went for Postgraduation (MSc) (1999-2001) in Microbiology from Guru Nanak Dev University, Amritsar, Punjab, India. Later she pursued for PhD (2001-2008) on the topic Experimental Medicine and Biotechnology from the Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Top